Salient Voice Symptoms in Primary Muscle Tension Dysphonia.

Introduction: Patients with primary muscle tension dysphonia (pMTD) commonly report symptoms of vocal effort, fatigue, discomfort, odynophonia, and aberrant vocal quality (eg, vocal strain, hoarseness). However, voice symptoms most salient to pMTD have not been identified. Furthermore, how standard vocal fatigue and vocal tract discomfort indices that capture persistent symptoms-like the Vocal Fatigue Index (VFI) and Vocal Tract Discomfort Scale (VTDS)-relate to acute symptoms experienced at the time of the voice evaluation is unclear.

Basic Science and Pathogenesis.

Background: Alzheimer's disease (AD) is neurodegenerative disease brought on by a combination of changes in multiple pathways that conglomerate to promote disease progression. AD often occurs alongside comorbid diseases, most often immune or vascular in nature, which have been shown to further increase AD risk. We previously showed that known AD variants also associate with secondary diseases in these categories, including rheumatoid arthritis, ischemic myocardial infarction, and both Type 1 and Type 2 diabetes.

WITHDRAWN: There is often - But not always - An alternative!

The Publisher regrets that this article is an accidental duplication of an article that has already been published, https://doi.org/10.1016/j.

Experience with remote electronic portal imaging device-based dosimetric auditing for static and rotational intensity modulated radiotherapy.

The aim of this work was to evaluate results of a remote electronic portal imaging based dosimetric auditing method using Task-Group 218 clinical gamma evaluation criteria (3%,2 mm, 10% dose threshold). For intensity modulated radiation therapy the results were (mean ± 1 SD) 97.9 ± 4.

Medicare Advantage Population in the United States: Outcomes of Patients with Asthma Treated with ICS/LABA Before and After Initiation with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI).

Introduction: The clinical benefits of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) have been demonstrated in clinical trials. There is limited evidence regarding the effectiveness and economic outcomes associated with FF/UMEC/VI use in US clinical practice. This real-world study assessed asthma-related exacerbations, healthcare resource utilization (HRU), and healthcare costs among a Medicare Advantage-insured population before and after initiation of FF/UMEC/VI in patients with asthma previously treated with an inhaled corticosteroid/long-acting β-agonist (ICS/LABA).